{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:50:11Z","timestamp":1782420611141,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pcl.2026.02.007","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:02:56Z","timestamp":1775851376000},"page":"727-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Landscape for Atopic Dermatitis Therapies"],"prefix":"10.1016","volume":"73","author":[{"given":"Stephanie Munie","family":"Waggett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milaan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Wine Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pcl.2026.02.007_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: clinical implications","volume":"40","author":"Kim","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.pcl.2026.02.007_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/354250","article-title":"Atopic dermatitis: natural history, diagnosis, and treatment","volume":"2014","author":"Thomsen","year":"2014","journal-title":"ISRN Allergy"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2133.2006.07538.x","article-title":"A systematic review of the safety of topical therapies for atopic dermatitis","volume":"156","author":"Callen","year":"2007","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.pcl.2026.02.007_bib8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaci.2005.04.006","article-title":"Report of the topical calcineurin inhibitor task force of the American College of allergy, asthma and immunology and the American Academy of allergy, asthma and immunology","volume":"115","author":"Fonacier","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000086431","article-title":"Consensus statement on the safety profile of topical calcineurin inhibitors","volume":"211","author":"Bieber","year":"2005","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.pcl.2026.02.007_bib52","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40257-024-00855-2","article-title":"Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: pooled results from two randomized phase 3 studies","volume":"25","author":"Eichenfield","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.pcl.2026.02.007_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.pcl.2026.02.007_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"10.1016\/j.pcl.2026.02.007_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","article-title":"Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials","volume":"160","author":"Simpson","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.pcl.2026.02.007_bib53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5\u20136","key":"10.1016\/j.pcl.2026.02.007_bib14","first-page":"897","article-title":"Systemic therapy for atopic dermatitis in children and adolescents: a US expert consensus","volume":"240","author":"Eichenfield","year":"2024","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.pcl.2026.02.007_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib17","doi-asserted-by":"crossref","first-page":"s573","DOI":"10.25251\/skin.10.supp.573","article-title":"Long-term safety and efficacy of tralokinumab in adults and adolescents with moderate-to-severe atopic dermatitis treated for up to 6 years","volume":"9","author":"Blauvelt","year":"2025","journal-title":"J of Skin"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0319400","article-title":"Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: a systematic review and network meta-analysis","volume":"20","author":"Liao","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib19","article-title":"Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.pcl.2026.02.007_bib21","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-Week, open-label, phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10451","key":"10.1016\/j.pcl.2026.02.007_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/bjd\/ljad268","article-title":"Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study","volume":"190","author":"Igarashi","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.pcl.2026.02.007_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of Follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.pcl.2026.02.007_bib25","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jdv.19280","article-title":"Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: results from phase 3 studies, including the long-term extension JADE EXTEND study","volume":"37","author":"Reich","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/bjd\/ljae404","article-title":"Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (level up)","volume":"192","author":"Silverberg","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"Torrelo","year":"2023","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.pcl.2026.02.007_bib29","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s13555-024-01243-8","article-title":"Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors","volume":"14","author":"Kirchhof","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/vaccines12010082","article-title":"Vaccinations in selected immune-related diseases treated with biological drugs and JAK inhibitors\u2014literature review and statement of experts from Polish dermatological society","volume":"12","author":"Narbutt","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"16","key":"10.1016\/j.pcl.2026.02.007_bib31","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.3390\/jcm12165409","article-title":"Treatment with methotrexate in infants and toddlers with atopic dermatitis: a retrospective multi-center study","volume":"12","author":"Barak Levitt","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.pcl.2026.02.007_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5021\/ad.2020.32.5.402","article-title":"Therapeutic efficacy and safety of methotrexate in moderate-to-severe atopic dermatitis: a retrospective study of Korean patients at tertiary referral hospital","volume":"32","author":"Lee","year":"2020","journal-title":"Ann Dermatol"},{"issue":"4","key":"10.1016\/j.pcl.2026.02.007_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.abd.2022.10.006","article-title":"Use of cyclosporine in children and adolescents with moderate to severe atopic dermatitis: clinical experience in a tertiary hospital","volume":"98","author":"Proen\u00e7a","year":"2023","journal-title":"An Bras Dermatol"},{"issue":"8","key":"10.1016\/j.pcl.2026.02.007_bib34","first-page":"979","article-title":"The use of cyclosporine in dermatology","volume":"11","author":"Dehesa","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2024.09.046","article-title":"Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in atopic dermatitis","volume":"92","author":"Paller","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.pcl.2026.02.007_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/pde.15327","article-title":"Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines","volume":"40","author":"Siegfried","year":"2023","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.pcl.2026.02.007_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/jdv.14066","article-title":"Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients","volume":"31","author":"Hern\u00e1ndez-Mart\u00edn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.pcl.2026.02.007_bib38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0190-9622(98)70325-1","article-title":"Cyclosporine consensus conference: with emphasis on the treatment of psoriasis","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2017.12.077","article-title":"An assessment of the use of antihistamines in the management of atopic dermatitis","volume":"79","author":"He","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.pcl.2026.02.007_bib40","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1590\/abd1806-4841.20175958","article-title":"Narrowband UV-B phototherapy in childhood atopic dermatitis: efficacy and safety","volume":"92","author":"Dayal","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjd.12580","article-title":"Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study","volume":"170","author":"Darn\u00e9","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/phpp.12615","article-title":"Treatment of paediatric eczema with narrowband ultraviolet light B therapy","volume":"37","author":"Hunjan","year":"2021","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s13555-022-00876-x","article-title":"Risankizumab in patients with moderate-to-severe atopic dermatitis: a phase 2, randomized, double-blind, placebo-controlled study","volume":"13","author":"Tyring","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10372","key":"10.1016\/j.pcl.2026.02.007_bib44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcl.2026.02.007_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/1750743X.2025.2464528","article-title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis","volume":"17","author":"Guttman-Yassky","year":"2025","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.pcl.2026.02.007_bib46","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","article-title":"Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis","volume":"155","author":"Weidinger","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"10.1016\/j.pcl.2026.02.007_bib47","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.3390\/nu16234128","article-title":"Vitamin D supplementation for treating atopic dermatitis in children and adults: a systematic review and meta-analysis","volume":"16","author":"Nielsen","year":"2024","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.pcl.2026.02.007_bib48","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","article-title":"Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase 3, randomized, vehicle-controlled study (CAPTAIN-AD)","volume":"149","author":"Park","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pcl.2026.02.007_bib49","article-title":"The impact of prebiotics, probiotics and synbiotics on the prevention and treatment of atopic dermatitis in children: an umbrella meta-analysis","volume":"13","author":"L","year":"2025","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.pcl.2026.02.007_bib50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","article-title":"A systematic review and expert Delphi consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and immunology","volume":"133","author":"Lieberman","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.pcl.2026.02.007_bib51","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1542\/peds.2005-1188","article-title":"Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years","volume":"117","author":"Paul","year":"2006","journal-title":"Pediatrics"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395526000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395526000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:41:11Z","timestamp":1782420071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395526000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0031395526000155"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2026.02.007","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Landscape for Atopic Dermatitis Therapies","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2026.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}